Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride

Archives of Pharmacal Research

Volumn 28, Issue 4, 2005, Pages 483-487

  Jun, Shik Choi ^a   Jin, Pil Burm ^b  

^a Chosun University   (South Korea)

^b Chosun Nursing College   (South Korea)

Author keywords

Bioavailability; Hepatic failure; Norverapamil; Pharmacokinetics; Verapamil

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CARBON TETRACHLORIDE; DRUG DERIVATIVE; NORVERAPAMIL; VERAPAMIL;

ANIMAL; ARTICLE; BIOAVAILABILITY; BLOOD; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER FAILURE; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; RABBIT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; CARBON TETRACHLORIDE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; LIVER FAILURE; MALE; RABBITS; VERAPAMIL;

EID: 22844451919     PISSN: 02536269     EISSN: 02536269     Source Type: Journal    
DOI: 10.1007/BF02977680     Document Type: Article

References (13)

1. Eichelbaum, M., Remberg, E. G., Schomerus, M., and Dengler, H. J., The metabolism of D, L(14C) verapamil in man. Drug Metab. Dispos., 7, 145-148 (1979).
2. Eichelbaum, M., Albrecht, M., Kliems, G., Schafer, K., and Somogyi, A., Influence of mesocaval shunt or surgery on verapamil kinetics, bioavailability and response. Brit. J. Clin. Pharmacol., 10, 527-529 (1980).
3. Eichelbaum, M., Mikus, G., and Vogelgesang, B., Pharmacokinetics of (+)-, (-)- and (±)-verapamil after intravenous administration. Brit. J. Clin. Pharmacol., 17, 453-458 (1984).
4. Fleckenstein, A., Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Ann. Rev. Pharmacol. Toxicol., 17, 149-166 (1977).
5. Freedman, S. B., Richmond, D. R., Ashley, J. J., and Kelly, D. T., Verapamil kinetics in normal subjects and patients with coronary artery spasm. Clin. Pharmacol. Ther., 30, 644-652 (1981).
6. Gould, B. A., Mann, S., Kieso, H., Bala Subramanian, V., and Raftery, E. B., The 24-hour ambulatory blood pressure profile with verapamil. Circulation, 65, 22-27 (1982).
7. Krecic-Shepard, M. E., Barnas, C. R., Slimko, J., and Schwartz, J. B., Faster clearance of sustained release verapamil in men versus women: Continuing observations on sex-specific differences after oral administration of verapamil. Clin. Pharmacol. Ther., 68, 286-292 (2000).
8. Lewis, G. R., Morley, K. D., Lewis, B. M., and Bones, P. J., The treatment of hypertension with verapamil. NZ. Medical J., 87, 351-354 (1978).
9. Rocci, M. L., and Jusko, W. J., LAGRAN program for area and moments in pharmacokinetic analysis. Computer Programs in Biomedicine, 16, 203-209 (1983).
10. Schomerus, M., Spiegelhaider, B., Stieren, B., and Eichelbaum, M., Physiologic disposition of verapamil in man. Cardiovasc. Res., 10, 605-612 (1976).
11. Schwartz, J. B., Abernethy, D. R., Taylor, A. A., and Mitchell, J. R., An investigation of the cause of accumulation of verapamil during regular dosing in patients. Brit. J. Clin. Pharmacol., 19, 512-516 (1985).
12. Somogyi, A., Albrecht, M., Kliems, G., Schafer, K., and Eichelbaum, M., Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. Brit. J. Clin. Pharmacol., 12, 51-60 (1981).
13. Woodcock, B. G., Rietbrock, I., Vohringer, H. F., and Rietbrock, N., Verapamil disposition in liver disease and intensive-care patients: Kinetics, clearance, and apparent blood flow relationships. Clin. Pharmacol. Ther., 29, 27-34 (1981).